Abstracts Clinical Lymphoma, Myeloma & Leukemia September 2023 S324 the treatment of HCL. Materials and Methods: In this retrospective single-center observational study, 60 patients diagnosed with HCL based on the WHO 2008 criteria were treated with either CLAD or R-CLAD. Clinical and laboratory data were collected from medical records and electronic sources. Complete response (CR), minimal residual disease (MRD), relapse rates, and overall survival (OS) were compared between the two groups. Results: The CR rate at 6 months after treatment was 96.4% in the R-CLAD group and 81.2% in the CLAD group. MRD negativity was observed in 89% of patients in the R-CLAD group and 78% in the CLAD group at 6 months post-treatment. The relapse rate was 10.7% after R-CLAD treatment and 28.1% after CLAD treatment. The mortality rate was lower in the R-CLAD group compared to the CLAD group (3.6% vs 25%). Median OS was not reached in either group, but the 2-year survival rate was 95.2% in the R-CLAD group and 78.1% in the CLAD group. Conclusion: Our findings suggest that the combination of cladribine and rituximab is more effective in treating HCL than cladribine alone, with higher CR rates, lower relapse rates, and improved survival outcomes. Further research with larger patient cohorts is needed to confirm these results. Keywords: hairy cell leukemia, cladribine, rituximab, treatment, retrospective study CLL-241 A Survey of Chronic Lymphocytic Leukemia Treatment Approaches in Turkey: A Turkish Hematology Network Group Study Birol Güvenç MD1, Mehmet Ali Özcan MD2, Mehmet Sönmez MD3, Mehmet Turgut MD4, Ali Ünal MD5 1Cukurova University Faculty of Medicine, Department of Hematology, Adana, Turkey. 2Dokuz Eylül University Faculty of Medicine, Division of Hematology, Izmir, Turkey. 3Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey. 4Ondokuz Mayıs University Faculty of Medicine, Division of Hematology, Samsun, Turkey. 5Erciyes University Faculty of Medicine, Division of Hematology, Kayseri, Turkey Background: Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults, with a varied clinical course and treatment landscape. The Turkish Hematology Network Group (THNG) conducted a survey to gather real-world outcomes of CLL treatment approaches in Turkey. Methods: A total of 79 hematologists participated in the survey, which was comprised of 34 questions addressing the diagnosis, treatment, and management of CLL patients. The survey aimed to evaluate current practices in Turkey, explore potential regional differences, and assess adherence to international guidelines. Results: The survey revealed that the majority of respondents (87.3%) were guided by the iwCLL guidelines for CLL management. Fluorescence in situ hybridization (FISH) was the most used technique for cytogenetic testing (93.4%). FCR (fludarabine, cyclophosphamide, and rituximab) was the preferred first-line treatment (69.7%), followed by BR (bendamustine and rituximab) (16.7%). Venetoclax-based regimens were predominantly used for relapsed or refractory CLL (62.3%). Minimal residual disease (MRD) testing was performed by 42.1% of respondents, with a higher rate among university-based physicians. Regional differences in treatment approaches were observed, with FCR use more common in the Marmara region and BR use more common in the Central Anatolia region. Ibrutinib was the preferred treatment for patients with TP53 abnormalities (75.95%). The CLL IPI was used by 44.3% of respondents in their clinical practice. Conclusion: The THNG survey demonstrates that Turkish hematologists and oncologists largely adhere to international guidelines for CLL management. However, regional variations and gaps in the adoption of certain diagnostic and treatment modalities, such as MRD testing, highlight the need for continuous education and collaboration among healthcare professionals. Further studies are warranted to evaluate the impact of these variations on patient outcomes. Keywords: chronic lymphocytic leukemia, CLL, Turkish Hematology Network Group (THNG), CLL treatment, regional differences Türkiye CLL-247 Updates of the Epidemiological Profile and Management of Chronic Lymphocytic Leukemia Vasile Musteata MD, PhD, MPH1,2, Vera Chirca MD1, Stela Pinzari MD2, Elena Covalschi MD1,2, Larisa Musteata MD, PhD1, Irina Ceban MD2, Nina SghibnevaBobeico MD1,2, Djesilina Petkova MD1,2 1State University of Medicine and Pharmacy “N. Testemitanu”, Chisinau, Republic of Moldova. 2Institute of Oncology, Chisinau, Republic of Moldova Context: Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in Western Europe and North America, and mainly affects elderly persons. Objectives: The evaluation of the epidemiological, clinical and laboratory hallmarks, as well as treatment options of CLL. Design: We performed observational and cohort study. The diagnosis was proved on the basis of IWCLL criteria and immunophenotyping data. The stage of CLL was asserted according to Binet Staging System. Setting: The patients’ followup was performed at the comprehensive cancer center and related to the hospitalized and outpatient care. Participants: The study included 110 CLL patients treated at the Institute of Oncology from Moldova between 2015-2022. Interventions: The retrospective and prospective patients’ cohorts were evaluated. The mainly used antineoplastic regimens were monotherapy with chlorambucil and rituximab, R-CHOP, R-COP, RFC. The following research methods were applied: epidemiological, descriptive and comparative statistics, big data analytics. Main Outcome Measures: Complete response rate estimated for the short-term results, and overall survival (OS) – the long-term results. Results: CLL was diagnosed in 33 (30%) patients from Northern districts, in 15 (14%) from Southern districts and in 58 (53%) – from central districts. Fifty-nine (53.64%) newly diagnosed patients emerged from the urban areas. The largest age categories consisted of patients of 65-74 (38 [34%]) and 55-64 (41 [37%]) years old. The incidence of CLL among males (65 [59,3%]) was higher than among females (45 [40,7%]) (P<0.05). Out of 110 patients, 56 (50.91%) were retired pensioners, 19 (17.27%)
RkJQdWJsaXNoZXIy MTk3NTQxMg==